cyrilzakka/clinical-trials huggingface dataset:
Icare Versus Haag-Streit Applanation Tonometer

The clinical performance of Icare ONE Tonometer TA02 was compared to a Goldmann type applanation tonometer (Haag-Streit). Data was collected according to ANSI Z80.10-2003 (ISO 8612.2) standard. Subjects were eligible for the study if they had no exclusion criteria specified in the ANSI/ISO standard. One eye from 260 subjects was selected for the study. The minimum sample size according to the standard is 150. One eye of each subject was selected for the study by an investigator, based on the history of the patient, results of an external examination of the eye with slit lamp, keratometry readings, and prior knowledge of the intraocular pressure (IOP) range. The Icare ONE Tonometer TA02 in comparison to the reference tonometer (Goldmann type tonometer).


Eligibility Criteria:
Inclusion Criteria:

* subjects were eligible for the study if they had no exclusion criteria as specified by the ANSI/ISO standard

Subjects were selected according to the following exclusion criteria (as given in ANSI Z80.10-2003 and ISO 8612):

* subjects with only one functional eye
* those with one eye having poor or eccentric fixation
* high corneal astigmatism (i.e. those eyes displaying an oval contact image with the Goldmann tonometer)
* those with corneal scarring or who have had corneal surgery, including corneal laser surgery
* microphthalmos
* buphthalmos
* contact lens wearers
* dry eyes
* lid squeezers (blepharospasm)
* nystagmus
* keratoconus
* any other corneal or conjunctival pathology or infection
Promoting Contextually Cued PA Habits

The primary goal of this two-month pilot study is to measure the behavioral change induced by targeted habit formation reminders that are surfaced via an iPhone app and financial incentives that were offered conditional on using a personalized contextual cue for a daily walking habit. The data and user feedback collected during this study will also be used to optimize the design and content of the iPhone app, which will be tested in future, larger scale experimental research.

Subjects for this research are recruited on campus at Rensselaer Polytechnic Institute and the State University of New York at Albany, and their participation was incentivized. After meeting the eligibility criterion (including have at least some intrinsic motivation for increasing physical activity), downloading the project's iPhone app, and signing the project consent form, all participants will have their step count data recorded for an 8-week study period.

Existing interventions that have successfully improved study participants' health-related behaviors typically find that behavioral changes do not persist beyond 3 months after the intervention period. Fortunately, novel habit formation interventions from the psychology literature offer the potential for building long-term behavioral change and avoiding the common "relapse triangles" observed in these existing behavioral interventions. These new methods are based on the theory that habits are formed through the repetition of the same behavior in response to a stable, environmental cue. After an initial period of repetition, automaticity is formed, and the behavioral response becomes more effortlessly/unconsciously induced by the environmental cue. Behavioral reminders that reinforce a specific behavioral routine-environmental cue pair have been shown to support this initial period of habit formation; however, given the individualized nature of these reminders, a generalizable intervention method has not been developed and empirically tested. This research will use an iPhone app to examine the role of both general informational on contextually cued habits and the use of personalized reminders and financial incentives for using a daily physical activity contextual cue on the persistence of physical activity behavior after the intervention tools are withdrawn.

Eligibility Criteria:
Inclusion Criteria:

* 18+ years of age
* Have an existing wellness goal related to increasing physical activity
* Access to an iPhone with iOS 10 or above (in order to use the app)
* Proficiency in speaking and reading English

Exclusion Criteria:

* Have a major visual impairment
* Pregnancy
* Expected surgery
* A chronic or acute health condition that affects their ability to perform basic mobility tasks or light-aerobic exercise (e.g. heart disease, injured or missing limb, etc.)
Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study

Osteoporosis affects nearly half of all American women over age 50. During the teenage years, girls can increase bone growth to decrease their risk of osteoporosis later in life. This study will test whether girls can change their food intake and physical activity patterns in ways that will increase their bone growth during the mid-teen years.

Osteoporosis-related fractures incur an annual cost in the United States of more than $8 billion. Peak bone mass is achieved in the late teens and early 20s. An important component of a lifelong osteoporosis prevention strategy is to maximize bone mineral content during the teen years and establish lifestyle patterns that will help maintain bone mineral content through menopause. This trial will test the efficacy of a comprehensive lifestyle intervention to build bone and prevent bone loss among adolescent women 14 to 16 years of age.

Participants in this study will be randomized to either an intervention group or an attention control group. The intervention program includes a physical activity component involving high impact and spinal motion activities and a diet component rich in fruits, vegetables, and calcium. Participants will take part in group and individual meetings and activities and receive coaching telephone calls. Participants will be assessed at study entry and two annual follow-up visits. Primary outcome measures include objective measures (serum folate and carotenoids urinary sodium, lean body mass, accelerometer measure of physical activity) and self-reports.

Eligibility Criteria:
Inclusion Criteria

* High school freshman or sophomore
* Body mass index (BMI) from 16 through 23
* Member of Kaiser Permanente Northwest Health Plan
* Parent or guardian willing to participate

Exclusion Criteria

* Co-morbidity requiring a specific diet
* Medication which contraindicates consuming a high-fiber diet
* Life-threatening disease or other condition that would interfere with study participation
* Current or past medically or self-diagnosed eating disorder
* Current behaviors consistent with eating-related disorder
* Pregnancy
* Diagnosis of psychological disorder or difficulty within the past year
Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy

The purpose of this study is to compare the effect of the concentration of vasopressin, which is used as a method for reducing blood loss in robot-assisted laparoscopic myomectomy.

This study is to compare the effect of the concentration of vasopressin, which is used as a method for reducing blood loss in robot-assisted laparoscopic myomectomy. We would like to evaluate the feasibility and validity of this study for future Phase III randomized clinical trials through this preliminary randomized assignment study.

Uterine fibroids are the most common tumors in women, and uterine myomectomy, which is performed as a treatment for them, is basically a high risk of bleeding and blood transfusion. A common method to reduce intraoperative bleeding is to inject diluted vasopressin into the subserosal areas of the fibroids. However, no proper level of vasopressin dilution has been determined so far, so we want to determine an effective dilution concentration of vasopressin that can minimize side effects through this clinical trial.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent
* Age: 19-60 year-old women
* Plan of myomectomy for uterine leiomyomas
* Leiomyoma Subclassification System 2-7 (robot-assisted laparoscopic myomectomy is possible)
* American Society of Anesthesiologists Physical Status classification 1 or 2
* A person who understands the contents of the clinical trial, is cooperative with the trial, and is judged to be able to participate until the end of the study

Exclusion Criteria:

* Pregnancy or breastfeeding
* A single diameter of uterine leiomyoma is greater than 12 cm or more or multiple leiomyomas with more than five
* Suspicious disease of uterine malignancy
* Patient with has a history of pelvic surgery (cesarean section, myomectomy, etc.) and is expected to have severe pelvic adhesion
* A person who is hypersensitive or contraindicated to vasopressin
* A person who is hypersensitive or contraindicated to tranexamic acid
* Considered as inappropriate by the researcher's judgment
Intradialytic Exercise and Remote Ischaemic Preconditioning: a Cardioprotective Role ?

The aim of this clinical trial is to evaluate whether intermittent exercise and remote ischaemic preconditioning (rIPC) during haemodialysis (HD) can provide cardioprotection in adult patients (aged 20-79 years) undergoing HD for at least 3 months. The main questions to be answered are

Does intermittent exercise or rIPC reduce myocardial stunning during HD? Do these interventions have a beneficial effect on haemorheology, arrhythmias, systemic inflammation and HD efficiency? The investigators will compare three HD sessions: no intervention (HD-CONT), with moderate-intensity intermittent exercise (HD-EX), and with rIPC using cuff inflation (HD-rIPC) to see if HD6EX and HD-rIPC approaches offer enhanced cardioprotection.

Participants will:

Undergo three randomised HD sessions. Participate in 5 blocks of moderate-intensity exercise or rIPC during the HD sessions.

Have cardiac function and biomarkers assessed before, during and after HD.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged between 20 and 79 years.
* Patients on hemodialysis for more than 3 months.
* No engagement in regular exercise outside of dialysis.
* No prior exposure to intradialytic exercise within the past six months.
* No medical contraindications to physical activity.
* Life expectancy greater than 6 months.
* Patients with relative good echogenicity

Exclusion Criteria

* Patient is participating in another Category I interventional study, or has participated in another interventional study within the past 3 months
* The patient is in an exclusion period determined by a previous study
* The patient is under legal protection or under guardianship or curatorship It turns out to be impossible to give the patient informed information, or the patient refuses to sign the consent
* Pregnant, parturient or breastfeeding patient
* Patients with unstable coronary artery disease.
* Patients with peripheral artery disease (stage III or IV) in the lower limbs.
* Patients with limb amputation.
* Patients with musculoskeletal disorders impairing exercise.
* Presence of a pacemaker, cardiac stimulation device, or implantable cardioverter defibrillator (ICD).
* History of heart transplant.
* Patients with uncontrolled hypertension.
* Refractory anemia.
Early Reassessment of Intravenous Antiinfective Therapy Due to "Antiinfective Reminders" (AIR Study)

Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs and risk of complications. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.

Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs, risk of complications as well as higher workload on nursing. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.

Eligibility Criteria:
Inclusion criteria:

* all in-patients in treatment with an intravenous antiinfective for \>60h,
* hospitalized in a ward with computerized physician order entry (cpoe)

Exclusion criteria:

* outpatients,
* ward without cpoe,
* no intravenous antiinfective treatment
Tissue Microarray of Hematological Malignancies

The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients.

Firstly, clinical information is collected on all hematological malignancies diagnosed in our hospital district area retrospectively between the years 2000 and 2019. Clinical outcomes, laboratory results, clinically relevant diagnoses, characteristics defining clinical stage and established prognostic parameters are gathered.

Simultaneously a tissue microarray (TMA) of diagnostic samples is compiled using representative annotated tissue areas. This TMA is used in combination with additional control material to identify prognostic and predictive biomarkers.

A combined microarray dataset of hematological malignancies (Hemap) is utilized to point out genes of possible drug targets, disease specific markers, prognostic markers, or predictive markers.

The clinical datasets and Hemap dataset is ultimately utilized to gain knowledge, new tools for prognostication and diagnostics, and targets for treatment. Artificial intelligence -assisted differential diagnostics will be tested.

Eligibility Criteria:
Inclusion Criteria:

* hematological malignancy/neoplasm

Exclusion Criteria:

* Non-sufficient data available
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants

Subjects will be randomly assigned to 1 of 3 groups to receive the following vaccines: Group 1: 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP), Group 2: 7-valent pneumococcal conjugate vaccine (7vPnC) and DTaP, Group 3: DTaP alone. Group 3 subjects will also receive catch-up doses of Prevenar (commercial product of Prevenar in Japan) 13vPnC and 7vPnC will be blinded, and DTaP will be open-label. The main purpose of the study is to determine if the immune responses to 13vPnC are comparable to the immune responses to 7vPnC and if the immune responses to 13vPnC given with DTaP are comparable to those induced by DTaP given alone. In addition, the study aims to evaluate the side effects (safety profile) after vaccination of 13vPnC and 7vPnC when given with DTaP in healthy Japanese infants.


Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects between 3 to 6 months of age at the enrollment.
* Available for the entire study period and whose parent/legal guardian can be reached by telephone.
* Healthy infant as determined by medical history, physical examination, and judgement of the investigator.

Exclusion Criteria:

* Previous vaccination with licensed or investigational pneumococcal, diphtheria, tetanus, or pertussis vaccines.
* A previous anaphylactic reaction to any vaccine or vaccine-related component.
* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
* History of culture-proven invasive disease caused by S pneumoniae (eg, meningitis, bacteremia, osteomyelitis, arthritis).
* Infant who is a direct descendant (child, grandchild) of the study site personnel.
Study on the Effect of Electroacupuncture at Both Zusanli and at Both Yanglingquan Acupoints on Cardiovascular Activity

The purpose of this present study was to investigate the effect of electroacupuncture at both Zusanli and at both Yanglingquan acupoints on autonomic nerve modulating cardiovascular activity, and skin blood flow and skin temperature. The investigators use pulse rate variability to investigate autonomic nerve modulates cardiovascular function, and using distant skin blood flow and skin temperature recordings to investigate the relationship between the same names meridian of hand and foot.

A total of 24 adult healthy volunteer were studied, they received the three sessions of sham electroacupuncture, electroacupuncture at Zusanli and electroacupuncture at Yanglingquan, respectively. Each session was divided into three periods of before electroacupuncture, electroacupuncture, and post electroacupuncture. Each period was 20 min in duration. The ahead 15 min of the period was the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand; the final 5 min of the period was pulse rate variability recordings of left hand. The data was storage and analysis in a personal computer.

Eligibility Criteria:
Inclusion Criteria:

1. healthy volunteers without without cardiac disease, taking medications, smoking
2. before experiment, abstaining from caffeine, alcohol for 8 hours.
3. age between 20-40.

Exclusion Criteria:

1. volunteers with cardiac disease, taking medications, smoking
2. age greater than 40 or less than 20.
The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects

This study is a single-center, open-label study evaluating the pharmacokinetics, tolerability and safety of single dose oral brexpiprazole tablets in healthy Chinese subjects. A total of 30 healthy adult subjects are to be enrolled into the study. Three dose groups will be set up, with about 10 subjects in each dose group. Subjects will enter 1 mg, 2 mg and 4 mg dose groups in sequence.

A total of 30 healthy adult subjects are to be enrolled into the study. Three dose groups will be set up, with about 10 subjects in each dose group. Subjects will enter 1 mg, 2 mg and 4 mg dose groups in sequence.

After the clinical trial responsible physicians obtain the informed consent forms from subjects, the subjects will be screened 14 days to 1 days prior to taking the study drug (D-14\~D-1).

One day prior to dosing in each group (D-1), the included subjects are hospitalized On the next day (D1), after completed the hospitalization inspection, eligible subjects will be assigned subject numbers to start with the first dose, complete corresponding examination, stay in hospital for observation and be discharged on Day 4 of medication. On days 6, 8, 10, 12 blood samples are collected and safety evaluation will be performed. Telephone follow-up will be performed on day Day31.

Blood samples are collected to determine and evaluate blood concentrations of Brexpiprazole and its main metabolite DM-3411 before dosing, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours after dosing, with 18 sampling points in total.

Eligibility Criteria:
Inclusion Criteria:

* 1. Sign the informed consent form
* 2.At the age of 18\~45 years old (including upper and lower limits) when signing the informed consent form.
* 3.Body weight of not less than 50kg, BMI 19 \~ 24kg/m2 (including the upper and lower limits) \[ body mass index (BMI) = body weight (kg) / height2 (m2)\].

Exclusion Criteria:

* 1. Participated in any interventional clinical trial within 12 weeks prior to enrollment.
* 2.Drug abuse in the past 2 years or a history of abuse
* 3.Drinking alcohol more than 2 unit per day (1 unit= 360 ml beer , or 45 ml 4.0% alcohol, or 150 ml liquor, or 50 ml wine ) 6 months before the screening, or subjects can not stop drinking during the hospitalization
Ramanspectroscopy in Barrett's Esophagus

This study is being done to see if a new device, called near-infrared Raman spectroscopy, can provide similar information as that obtained from taking biopsies of the lining of your Barrett's esophagus

In the search for means to enhance the surveillance of BE, optical spectroscopy is emerging as a candidate with high potential. Optical spectroscopic techniques measure specific light-tissue interactions, such as fluorescence, elastic scattering, and Raman (inelastic) scattering, which provide objective and quantitative diagnostic information about the molecular and/or structural status of tissue. Moreover, optical spectroscopy has the capacity to identify tissue pathology in situ in a rapid and non-destructive fashion. Among the optical spectroscopic techniques, near-infrared Raman spectroscopy (NIRS) is particularly promising because of the wealth of molecular-specific information contained in its spectra

Eligibility Criteria:
Inclusion Criteria:

* Closed to further enrollment
EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABAD

In this Study i'll compare the effectiveness of two drugs used in acute exacerbation of asthma by their sideffects, complaince and improvement in the PRAM score. The better one would be adapted in our clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* i.Ages 2 to 12years ii. Previous history of asthma as diagnosed by a physician. iii. Presentation with acute exacerbation of asthma with symptoms of cough, wheeze, dyspnoea and oxygen saturation of less than 95% and with PRAM score of more than or equal to 6

Exclusion Criteria:

* i.Critical or life-threatening asthma i.e. patient with silent chest, cyanosis, drowsy, unable to verbalize, marked tachycardia and respiratory distress. ii.Known TB exposure iii.Fever more than 39. 5°C iv.Use of corticosteroids in previous 4 weeks v.Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients

This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects. This is an open-label exploratory study with no change of therapeutic behavior but with standardized neuropsychologic follow-up.

This study is planned to evaluate emotional disorders during treatment by IFN beta in RRMS subjects. This is an open-label, prospective, interventional, multicentric study with no change of therapeutic behavior but with standardized neuropsychologic follow-up. Subjects will undergo 13 evaluations (categorical and dimensional evaluations), 3 evaluations will be performed before the treatment (Baseline, Day 7 and 15) and 10 evaluations after the treatment (Month 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24).

Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects aged ≥ 18 years
* Subjects with RRMS
* Subjects with at least 2 relapses in the past two years (with last relapse finished or finishing)
* Subjects with indication of IFN beta treatment determined by the investigator
* Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

* Subjects with secondary progressive multiple sclerosis (MS) without relapse
* Subjects with ongoing acute relapse
* Subjects already being treated with interferon
* Subjects with corticoid therapy for less than 15 days
* Subjects presenting acute major depression or treated with anti-depressant therapy
* Subjects involved in another therapeutic study
* Subjects with any condition which could interfere with a good compliance of this study
* Other protocol-defined exclusion criteria may apply
Chronic Loose Stools Following Right-sided Hemicolectomy for Colon Cancer and the Association With Bile Acid Malabsorption and Small Intestinal Bacterial Overgrowth Using a Novel Sampling Device

The goal of this clinical research study is to learn about gastrointestinal symptoms in participants who have undergone SC or RC and their impact on the quality of life of these participants.

To estimate the microbiota and bile acid profiles at multiple levels of the small intestine and proximal neo-colon in patients after RC and participants after SC.

Eligibility Criteria:
Inclusion Criteria:

* Both men and women of all races and ethnic groups are eligible for this trial who meet the above criteria.

Exclusion Criteria:

* Children will not be enrolled in this study.
* Pregnant women will not be enrolled in this study.
* Cognitively impaired subjects will not be enrolled in this study.